Proteostasis therapeutics, inc. (PTI)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15
Revenue

-

0

0

0

5,000

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

4,060

1,715

1,451

1,158

1,234

1,201

1,070

807

Operating expenses:
Research and development

6,518

9,101

10,145

16,925

16,148

13,717

15,591

12,604

8,400

12,282

12,894

15,370

13,108

10,461

9,218

7,404

6,876

5,787

6,258

5,976

4,503

General and administrative

3,587

3,056

3,154

3,682

3,943

3,780

4,150

3,957

3,823

2,847

2,741

2,902

3,170

3,198

3,266

3,115

2,301

1,769

1,523

1,709

1,321

Total operating expenses

10,105

12,157

13,299

20,607

20,091

17,497

19,741

16,561

12,223

15,129

15,635

18,272

16,278

13,659

12,484

10,519

9,177

7,556

7,781

7,685

5,824

Loss from operations

-10,105

-12,157

-13,299

-20,607

-15,091

-17,497

-18,686

-15,718

-11,281

-13,507

-14,084

-17,125

-15,257

-9,599

-10,769

-9,068

-8,019

-6,322

-6,580

-6,615

-5,017

Interest income

207

215

224

297

357

342

171

194

165

126

155

169

191

190

36

20

-

-

-

-

-

Interest expense

3

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

189

209

201

Other income, net

23

86

242

292

316

255

87

46

90

-43

-25

-2

-30

-8

-38

-5

28

691

-281

205

-522

Net loss

-9,878

-11,856

-12,833

-20,018

-14,418

-16,900

-18,428

-15,478

-11,026

-13,424

-13,954

-16,958

-15,096

-9,417

-10,771

-9,053

-7,991

-5,631

-7,050

-6,619

-5,740

Accruing dividends on preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

1,378

3,026

2,459

2,152

2,087

Net loss attributable to common stockholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-9,417

-10,771

-9,053

-9,369

-7,940

-9,336

68

-7,827

Net loss per share—basic and diluted

-0.19

-0.23

-0.25

-0.39

-0.28

-0.36

-0.50

-0.43

-0.32

-0.51

-0.56

-0.68

-0.60

-0.38

-0.54

-0.47

-0.87

-

-

-

-

Weighted average common shares outstanding—basic and diluted

52,146

51,351

51,099

51,097

50,976

46,687

36,694

36,009

34,474

26,465

25,093

25,040

25,020

24,975

20,073

19,139

10,766

-

-

-

-

Other comprehensive income:
Unrealized gain on investments

36

-9

-17

15

17

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comprehensive loss

-9,842

-11,865

-12,850

-20,003

-14,401

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-